Great Plains Chapter of the American College of Cardiology

Latest in Cardiology from ACC.org

• DAPT-SHOCK-AMI: IV Cangrelor vs. Crushed Ticagrelor in Patients With Acute MI and Cardiogenic Shock
  Compared with crushed ticagrelor, intravenous (IV) cangrelor provided immediate and effective platelet inhibition with no increase in major bleeding and lower mortality rates in patients with acute myocardial infarction (MI) and cardiogenic shock.
• New Studies Explore Early Aspirin Withdrawal and Tailored Antiplatelet Strategies Following PCI
  Early withdrawal of aspirin following successful PCI for acute coronary syndrome and in low-risk patients following an acute myocardial infarction (MI) was the focus of two separate hot line trials presented at ESC Congress 2025.
• DUAL-ACS: 12-Month vs. 3-Month DAPT Following Acute MI
  Findings from the DUAL-ACS trial presented at ESC Congress 2025 suggest that three months of dual antiplatelet therapy (DAPT) following an acute myocardial infarction (MI) has the potential for better survival and lower bleeding rates compared with 12 months of DAPT.
• OPTION-STEMI: Immediate vs. Staged Complete Revascularization in Patients With STEMI and Multivessel CAD
  Noninferiority was not demonstrated in the OPTION-STEMI trial comparing immediate complete revascularization with staged complete revascularization in patients with STEMI and multivessel coronary artery disease. The findings, simultaneously published in The Lancet, were presented at ESC Congress 2025.
• Novel Adipokine Hypothesis Offers Framework to Explain Pathogenesis and Guide Treatment of HFpEF
  Heart failure with preserved ejection fraction (HFpEF) appears to arise “primarily from the expansion and dysfunctional transformation of visceral adipose tissue, leading to the secretion of altered suite of signaling molecules (adipokines), which causes systemic inflammation, plasma volume expansion, and cardiac hypertrophy and fibrosis,” according to the Adipokine Hypothesis authored by Milton Packer, MD, FACC, […]